MetLife Investment Management LLC Reduces Position in IQVIA Holdings Inc. (NYSE:IQV)

MetLife Investment Management LLC decreased its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 6.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 46,082 shares of the medical research company's stock after selling 3,423 shares during the quarter. MetLife Investment Management LLC's holdings in IQVIA were worth $10,920,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently made changes to their positions in IQV. FMR LLC boosted its stake in IQVIA by 38.7% during the third quarter. FMR LLC now owns 2,887,342 shares of the medical research company's stock valued at $684,213,000 after buying an additional 804,963 shares during the period. B. Metzler seel. Sohn & Co. Holding AG purchased a new position in IQVIA in the 3rd quarter worth $147,683,000. 1832 Asset Management L.P. boosted its position in IQVIA by 472.3% during the second quarter. 1832 Asset Management L.P. now owns 456,335 shares of the medical research company's stock valued at $96,487,000 after buying an additional 376,595 shares during the period. Renaissance Technologies LLC purchased a new position in shares of IQVIA in the second quarter worth about $70,610,000. Finally, Impax Asset Management Group plc boosted its holdings in IQVIA by 19.3% during the 2nd quarter. Impax Asset Management Group plc now owns 1,635,201 shares of the medical research company's stock valued at $344,998,000 after acquiring an additional 264,555 shares during the period. 89.62% of the stock is owned by institutional investors.

IQVIA Stock Down 0.2 %

Shares of IQVIA stock traded down $0.47 on Friday, reaching $200.96. The company's stock had a trading volume of 513,712 shares, compared to its average volume of 1,174,636. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76. The company has a market capitalization of $36.47 billion, a price-to-earnings ratio of 26.37, a P/E/G ratio of 2.07 and a beta of 1.51. The firm's fifty day simple moving average is $218.67 and its two-hundred day simple moving average is $226.20. IQVIA Holdings Inc. has a 52 week low of $187.62 and a 52 week high of $261.73.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. Leerink Partners reiterated an "outperform" rating and issued a $248.00 price objective (down previously from $260.00) on shares of IQVIA in a research report on Tuesday, November 19th. Robert W. Baird decreased their price objective on shares of IQVIA from $256.00 to $223.00 and set a "neutral" rating on the stock in a research report on Friday, November 1st. Deutsche Bank Aktiengesellschaft dropped their target price on shares of IQVIA from $270.00 to $265.00 and set a "buy" rating for the company in a report on Friday, November 1st. Barclays cut their price objective on IQVIA from $260.00 to $255.00 and set an "overweight" rating on the stock in a research report on Friday, November 1st. Finally, Evercore ISI decreased their target price on IQVIA from $270.00 to $265.00 and set an "outperform" rating for the company in a report on Tuesday, October 8th. Five equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $256.50.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.